Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Active, not recruiting · NCT04324112 · Registry updated 2026-06-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-06-12 | NCT04324112 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | United States | 800 |